Le Lézard
Classified in: Health, Business
Subject: VEN

Cathay Capital Announces Investment in Parkview Dental Partners


Investment will drive further expansion within the $155 billion US dental services market

NEW YORK, Nov. 6, 2023 /PRNewswire/ -- Private equity firm Cathay Capital announced today that it has invested in dental service organization (DSO) Parkview Dental Partners. This investment is the inaugural North American investment from Cathay's Growth Private Equity Fund (Small Cap IV), which announced a final close in June 2023. Cathay's investment, in partnership with Parkview's management team, will accelerate the Company's expansion in Florida's $9 billion dental services market.

Founded in 2018 in Sarasota, Florida, Parkview is a DSO that currently manages 22 dental practices that provide both general dentistry and specialty dental services. Parkview operates in the dynamic Southwest Florida market, characterized by population growth at 3x the national average, an aging population with higher dental care needs, and robust GDP growth. The Southwest Florida dental market remains highly fragmented, with a large number of unaffiliated dentists in the region. The growth in patients, dental procedures, dentists, and support staff in the Company's footprint is expected to be above the national average. Since its founding, Parkview has expanded from eight practices to 22 practices today, having grown revenue at a 50% CAGR since 2019 through organic initiatives and by successfully completing accretive acquisitions. Through the new partnership with Cathay, the Company will look to scale by acquiring new practices and adding ancillary dental services while remaining focused on clinical excellence and high-quality patient and provider experiences.

Mark Woods, Partner and Head of North American Private Equity at Cathay Capital, said, "We are excited to partner with Parkview Dental Partners as it is uniquely positioned in the DSO market. The company has a talented management team, attractive geography, and a well-developed operational playbook. We look forward to partnering with the team as they take advantage of favorable tailwinds to scale and expand."

Ricky Roman, Director at Cathay Capital, added, "The Cathay team looks forward to leveraging our healthcare services and buy-and-build experience to accelerate the growth of Parkview as the Company seeks to expand on its market-leading position in Southwest Florida."

Parkview CEO Will Schlotthauer said, "Our partnership with Cathay begins an exciting chapter for Parkview, as we look to become the pre-eminent Florida DSO supporting like-minded dentists who want to focus on providing clinically excellent care and a great patient experience. We are excited to benefit from Cathay's track record of scaling businesses while also having a growth mindset and a partnership-like approach with management teams and stakeholders.  This new partnership is uniquely positioned to accelerate Parkview's growth to become the market leader in the Southeast.  Cathay's experience with a "buy and build" strategy along with its adherence to driving culture aligns perfectly with Parkview's goals."

The transaction featured material rollover investment from Parkview's existing management team, including Will Schlotthauer, CEO, and Dr. Kenneth Liszewski, Founder and Chief Development Officer, as well as prior owner Parkstone Growth Partners. Live Oak Banking Company and Barings provided a unitranche credit facility in the recapitalization. Barings also provided an equity co-investment alongside Cathay Capital. Provident Healthcare Partners, LLC acted as the exclusive financial advisor to the Sellers.

About Parkview

Parkview is a dentist-founded dental growth & management partnership that is decidedly different from corporate DSOs. Based in Sarasota, Florida, our mission is to support like-minded dentists who want to focus on providing clinically excellent care and a great patient experience, while we provide the highest level of operational support and opportunities for professional growth.  For more information visit: www.parkviewdp.com 

About Cathay Capital

Cathay Capital is a global private equity and venture capital investment firm supporting healthcare, technology and consumer companies throughout North America, Europe, and Asia. The firm helps middle-market companies and startups navigate opportunities for growth, international expansion, and sustainable transformation. Cathay is the partner of choice for companies aspiring to lead markets and make a positive impact. Its platform connects people with global reach and local expertise ? from investors and entrepreneurs to management teams and leading corporations ? to share knowledge, the tools to scale and to transform businesses.

Founded in 2007 with a strong entrepreneurial heritage, Cathay Capital now manages more than $5.5 billion in assets. It has made over 250 investments in verticals including healthcare, technology, and consumer from offices in Paris, New York, San Francisco, Munich, Berlin, Madrid, Shanghai, Beijing, Shenzhen, and Singapore.  For more information, visit: www.cathaycapital.com.

Cathay Capital Contacts:

Mark Woods, Partner, [email protected], +1 203 273-1865

Ricky Roman, Director, [email protected], +1 203 508 0125

Parkview Contact:

Will Schlotthauer, Chief Executive Officer, [email protected], +1 941 524-5083

SOURCE Cathay Capital


These press releases may also interest you

at 20:05
Organovo Holdings, Inc. ("Organovo" or the "Company"), a clinical stage biotechnology company focused on developing novel treatment approaches based on demonstration of clinical promise in three-dimensional (3D) human tissues, today announced the...

at 20:00
Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology...

at 19:30
NCPDP announced today highlights from its 2024 Annual Technology & Business Conference, Innovation Starts Here. "NCPDP's standards and guidance are inherently innovative, and the work we continue to do will expand interoperability to support the...

at 19:25
Edwards Lifesciences today announced the European launch of the SAPIEN 3 Ultra RESILIA valve, the only transcatheter aortic heart valve to incorporate the company's breakthrough RESILIA tissue technology, designed to extend the valve's durability.*...

at 19:20
DaVinci Laboratories, a division of FoodScience, LLC of Williston, Vermont is recalling 72 bottles of Amyloid Complete because it may contain undeclared shellfish (Shrimp and Crab). People who have an allergy or severe sensitivity to shellfish run...

at 19:13
TOTAL REVENUE OF $67.5 MILLION FOR FIRST QUARTER 2024 VS $56.3 MILLION IN 2023, AN INCREASE OF 20%HOSPITAL DIVISION VISITS OF 40,068 FOR THE FIRST QUARTER 2024 VS VISITS OF 33,085 IN 2023, AN INCREASE OF 21.1%HOSPITAL DIVISION OPERATING INCOME OF...



News published on and distributed by: